Literature DB >> 12725867

Conformation, action, and mechanism of action of neuromuscular blocking muscle relaxants.

Chingmuh Lee1.   

Abstract

Since curare was introduced into clinical anaesthesia in 1942, efforts to create better neuromuscular blocking (NMB) muscle relaxants have continued. Today, muscle relaxation remains a mainstay of modern anaesthesia and intensive care. Through manipulation of the traditional structure-action relationships, many new and improved muscle relaxants have been created, and several have been brought to clinical use. However, structure-action relationship is inconsistent and has its limits. Using computer-aided molecular conformational analyses, the conformation-action relationships of NMB agents of various chemical classes have been explored. Conformation, no less than structure, of the NMB agents has shed new light on their mechanisms of action. By reflection, the conformations also suggest new details of the topology of the receptive sites of the nicotinic acetylcholine receptor modeled for the motor endplate of the skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12725867     DOI: 10.1016/s0163-7258(03)00030-5

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  3 in total

1.  High gender -specific susceptibility to curare- a neuromuscular blocking agent.

Authors:  Santosh K Maurya; Muthu Periasamy; Naresh C Bal
Journal:  Biol Res       Date:  2013       Impact factor: 5.612

2.  Comparative Analysis of the Anesthesia Effect of Cisatracurium Besylate and Mivacurium Chloride Otolaryngology Surgery.

Authors:  Shibin Huang; Qi Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-18       Impact factor: 2.650

3.  Effects of neuromuscular presynaptic muscarinic M1 receptor blockade on rocuronium-induced neuromuscular blockade in immobilized tibialis anterior muscles.

Authors:  Yong Beom Kim; Hong-Seuk Yang; Ha Jung Kim; Hey-Ran Choi; Junyong In; Soon-Young Yoon; Young Jin Ro
Journal:  Clin Exp Pharmacol Physiol       Date:  2018-08-30       Impact factor: 2.557

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.